Noticias y Actualizaciones de Avalyn

Avalyn Pharma (AVLN) Following AP02 Phase 1 Data Is Its Valuation Too Pricey

Avalyn Pharma (AVLN) is back on investor screens after Respiratory Research published full Phase 1 d...

Sep 23, 2026 • Yahoo Finance

Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile

Results validate Avalyn’s approach of delivering established antifibrotic medicines directly to th...

Sep 21, 2026 • Markets Insider

Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors

Avalyn Pharma Inc. (Nasdaq: AVLN) (“Avalyn” or the “Company”), a clinical-stage biopharmaceu...

Sep 16, 2026 • Markets Insider

Avalyn Publishes Phase 1 Data Supporting Lung-Targeted AP02 In Lung Disease

Avalyn Pharma Inc. ( AVLN) reported that Respiratory Research has published detailed results from tw...

Sep 22, 2026 • RTTNews

Avalyn to Participate in the Jefferies Global Healthcare Conference

BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biophar...

May 27, 2026 • Yahoo Finance

Avalyn’s New Twist on Older Lung Disease Drugs Attracts $175M for Clinical Trials

The lung disease idiopathic pulmonary fibrosis (IPF) has few available treatments, and that medical ...

Sep 30, 2023 • MedCity News

Avalyn Completes Oversubscribed $100 Million Series D Financing to Further Advance Clinical Development of Novel Inhaled Therapies for Pulmonary Fibrosis

CAMBRIDGE, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmace...

Jul 22, 2025 • manilatimes

Avalyn Pharma outlines inhaled fibrosis push after IPO, with pivotal data ahead

Avalyn Pharma (NASDAQ:AVLN) executives outlined the company's inhaled pulmonary fibrosis strategy at...

Jun 05, 2026 • MSN

Avalyn Announces Pricing of Upsized Initial Public Offering

BOSTON, April 29, 2026 (GLOBE NEWSWIRE)-- Avalyn Pharma Inc. (Nasdaq: AVLN) ("Avalyn”), a clinical...

Apr 29, 2026 • manilatimes

Inhaled drug developer Avalyn files for U.S. IPO

Avalyn Pharma (AVLN), a biotech focused on developing inhaled therapeutics for the lung disorder pul...

Apr 10, 2026 • Seeking Alpha

Lung disease drug developer Avalyn surges on public debut

Avalyn Pharma (AVLN), a biotech focused on developing inhaled therapeutics for the lung disorder pul...

Apr 30, 2026 • Seeking Alpha

Avalyn Pharma Publishes Phase 1 Data Highlighting AP02's Lung-Targeted Delivery and Encouraging Safety Profile

Avalyn Pharma Inc. announced that Respiratory Research has published detailed results from two Phase...

Sep 21, 2026 • MarketScreener

Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary Fibrosis

In silico modeling predicts robust AP01 distribution in healthy and fibrotic lungs, even in severe d...

Sep 08, 2026 • Yahoo Finance UK

Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: AVLN), a clinical-stage biopharmaceutical compa...

Sep 08, 2026 • Yahoo Finance

Avalyn Pharma Inc.(NasdaqGS:AVLN) added to S&P Pharmaceuticals Select Industry Index

Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company engaged in inhaled therapies to tra...

Sep 20, 2026 • MarketScreener

Avalyn Pharma Inc. (AVLN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 1:50 PM EDTCompany Partic...

Sep 14, 2026 • Seeking Alpha

Avalyn Pharma Inc AVLN

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies...

Sep 18, 2026 • Morningstar%2c Inc.

Avalyn Pharma Adds Former FDA Executive To Board As AP01, AP02 Trials Progress

Avalyn is also advancing AP03, an inhaled fixed-dose combination of pirfenidone and nintedanib, desi...

Sep 16, 2026 • RTTNews

Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026

Avalyn aims to transform the treatment paradigm for pulmonary fibrosis and other serious, rare respi...

Aug 24, 2026 • Yahoo Finance

Avalyn Showcases Clinical Data Across Multiple Pulmonary Fibrosis Programs at ATS 2025

The MarketWatch News Department was not involved in the creation of this content. Topline results fo...

May 20, 2025 • MarketWatch

Avalyn Announces Publication Demonstrating Correlation Between Imaging, Improved Lung Function, and Quality of Life with AP01 in Patients with Idiopathic Pulmonary Fibrosis

Findings provide early evidence supporting potential disease-modifying activity of AP01 (inhaled pir...

Mar 25, 2026 • manilatimes

Avalyn Pharma Expands Executive Team with Appointment of Howard M. Lazarus, MD, FCCP to the Role of Chief Medical Officer

Seattle, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical co...

Aug 07, 2023 • Yahoo Finance

Slowdive Share "Avalyn" Live Recording to Mark 25th Anniversary of Debut EP

25 years ago today, Slowdive released their self-titled debut EP on Creation. To mark the occasion, ...

Nov 05, 2015 • Pitchfork

Avalyn Strengthens Leadership Team to Support Long-Term Growth with Appointments of Industry Leaders Adam Golden and Frank Salisbury

BOSTON, April 27, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical co...

Apr 27, 2026 • Nasdaq

Avalyn Pharma Begins IPO Process For Pulmonary Fibrosis Pipeline

Avalyn Pharma Inc. (AVLN) has filed to raise capital for its treatment pipeline development, accordi...

Apr 10, 2026 • Seeking Alpha

Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Completed enrollment of MIST global Phase 2b trial of AP01 with 398 patients; topline data expected ...

Aug 12, 2026 • Business Insider

Avalyn heads to Nasdaq with oversized $300M IPO to fund reformulated respiratory drugs

Avalyn Pharma has overshot its expectations with a $300 million IPO that the biotech will use to fun...

Apr 29, 2026 • FierceBiotech

Avalyn Pharma’s CEO Leads Workshop on Clinical Strategy at IPF Summit

Seattle, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical c...

Sep 18, 2023 • Yahoo Finance

Avalyn, in pursuit of better lung drugs, banks $300M in an IPO

Avalyn Pharma on Wednesday raised $300 million in a large initial public offering that'll support de...

Apr 29, 2026 • Yahoo Finance

Avalyn Pharma raises $300M in IPO, shares surge 64% on first day of trading

To continue reading this content, please enable JavaScript in your browser settings and refresh this...

Apr 30, 2026 • The Business Journals